Evidence map›Paper›PMID 39902042›Full record

ArticleFrontiers in immunology2024

Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.

Sylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, Luc-Matthieu Fornecker, Bernard Drenou, Caroline Jacquet, Fatiha Merabet, Milena Kohn, Florence Quélin, Angela Jackson and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05050461 (Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05050461 naterminatednot on this map

Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma

TypeinterventionalSponsorVersailles HospitalRan2021 to 2023Enrolled120ConditionsNon-hodgkin Lymphoma,B Cell, Vaccination FailureArmsImmunological analyses
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sylvain Lamure *Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France.
Houria Hendel Chavez *Laboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, France.
Marie-Ghislaine de Goër de Herve *Laboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, France.
Luc-Matthieu ForneckerService d'Hématologie, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Bernard DrenouService d'Hématologie, Groupe Hospitalier de Mulhouse Sud Alsace, Mulhouse, France.
Caroline JacquetService d'Hématologie, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Nancy, France.
Fatiha MerabetService d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France.
Milena KohnService d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France.
Florence QuélinMaison de la Recherche Clinique, Centre Hospitalier de Versailles, Le Chesnay, France.
Angela JacksonUniversité Paris-Saclay, Université de Versailles - Saint-Quentin-en-Yvelines (UVSQ), Inserm, Équipe "Exposome et Hérédité", Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France.
Sylvain ChoquetPitie-Salpetriere Hospital, Assistance Publique - Hôpitaux de Paris (APHP)- Sorbonne University, Paris, France.
Rémy DuléryService d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Inserm UMRs 938, Paris, France.
Yassine Taoufik *Laboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, France.
Caroline Besson *Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma treatment, CD4, CD8, and CD19 cell dropped. While functional-specific CD4 and CD8 T-cell responses to SARS-CoV-2 were unaffected, vaccination in patients on treatment induced low specific antibody titers, contrasting with a preserved serological response when vaccination was completed before treatment initiation. Those findings reinforce a vaccinal strategy based on completion before lymphoma treatment, with a booster administered afterward.

Indexed as

B-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesLymphoma, B-CellSARS-CoV-2AdultAgedAntibodies, ViralAntigens, CD20BNT162 VaccineFemaleHumansMaleMiddle AgedAntibodies, ViralAntigens, CD20BNT162 VaccineCOVID-19 VaccinesRituximabanti-CD20chemotherapyCOVID-19 vaccineimmune responselymphoma

Identifiers

PMID39902042
PMCPMC11788169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.